3.26
+5.16%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SIGA Technologies
From its filings with the US Securities and Exchange Commission
SIGA Technologies is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SIGA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $94.6m and net income of $23.3m. At that date it held total assets of $219.5m and shareholders' equity of $198.8m.
We are a commercial-stage pharmaceutical company. The Company sells its lead product, TPOXX® (“oral TPOXX®,” also known as "tecovirimat," "Tecovirimat-SIGA," or "TEPOXX (tecovirimat)" in certain international markets), to the U.S. Government and international governments (including government affiliated entities). In certain international markets, the Company may sell TPOXX® through a distributor. Additionally, the Company sells the intravenous formulation of TPOXX® ("IV TPOXX®") to the U.S. Government.
TPOXX® is an antiviral drug for the treatment of human smallpox disease caused by variola virus. On July 13, 2018, the United States Food & Drug Administration (“FDA”) approved the oral formulation of TPOXX® for the treatment of smallpox. The Company has been delivering oral TPOXX® to the U.S. Strategic National Stockpile ("Strategic Stockpile") since 2013.
In addition to being approved by the FDA, oral TPOXX® (tecovirimat) has received regulatory approval from the European Medicines Agency ("EMA"), Health Canada, the Medicines and Healthcare Products Regulatory Agency ("MHRA") of the United Kingdom, and the Japanese Pharmaceuticals and Medical Devices Agency ("PMDA"). The EMA, MHRA and PMDA approved oral TPOXX® for the treatment of smallpox, monkeypox ("mpox"), cowpox, and vaccinia complications following vaccination against smallpox. Health Canada approved TPOXX® for the treatment of smallpox.
Quoted from its 10-K, filed 10 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Sept 1997
- Employees
- 49
- Website
- siga.com ↗
- Head office
- 31 EAST 62ND STREET, NEW YORK, NY, 10065
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. Diem NguyenChief Executive Officer, Director, since 2024$4.4m
- Mr. Daniel LuckshireChief Financial Officer, Executive Vice President, Corporate Secretary$1.5m
- Dr. Dennis HrubyExecutive Vice President, Chief Scientific Officer$1.5m
- Mr. Lawrence MillerGeneral Counsel, Corporate Secretary$2.2m
- Mr. Jaymie DurnanIndependent Director$218,577
- Mr. Harold FordIndependent Director$219,827
- Gen. (Retd.) John KeaneIndependent Director
- Mr. Joseph MarshallIndependent Director$236,077
- Dr. Gary NabelIndependent Director$217,327
- Mr. Julian NemirovskyIndependent Director$234,827
- Dr. Holly PhillipsIndependent Director$222,327
- Ms. Suzanne HarnettSenior Vice President - Corporate Affairs and Investor Relations, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 27
- Environment
- 29
- Social
- 26
- Governance
- 26
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- SIGA Technologies Inc possesses a robust intellectual property portfolio that includes patents and licensing agreements. This provides the company with a competitive advantage and protects its innovative products from imitation or unauthorized use.
- SIGA Technologies Inc has established valuable partnerships and collaborations with leading pharmaceutical companies, research institutions, and government agencies. These partnerships boost research and development efforts, enhance product reach, and support the company's growth strategy.
Weaknesses
- SIGA Technologies Inc relies heavily on a few key products for its revenue generation. This limited product portfolio exposes the company to risks associated with market demand, product obsolescence, and competition. Diversification of its product line could mitigate these risks.
- SIGA Technologies Inc heavily depends on government contracts for a significant portion of its revenue. Changes in government policies, budget cuts, or delays in contract approvals could have a negative impact on the company's financial performance.
Opportunities
- The global market for antiviral drugs is expanding, driven by increasing incidents of viral infections and outbreaks. SIGA Technologies Inc can capitalize on this opportunity by developing and marketing new antiviral drugs, expanding its market presence, and increasing revenue.
- Rapid advancements in technology, such as genomics and nanotechnology, present opportunities for SIGA Technologies Inc to enhance its drug development processes, improve product efficacy, and stay ahead of the competition. Embracing and investing in emerging technologies can drive innovation and growth.
Threats
- The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies. SIGA Technologies Inc faces the threat of intense competition in terms of product development, pricing, and market share. Sustained investment in research and development and differentiation strategies are essential to stay competitive.
- The pharmaceutical industry is subject to stringent regulatory requirements and compliance standards. Adhering to these regulations can be costly and time-consuming for SIGA Technologies Inc. Any non-compliance issues or regulatory changes can potentially disrupt operations and hinder product development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.